Anna Norhammar1, Johan Bodegard2, Thomas Nyström3, Marcus Thuresson4, Klas Rikner5, David Nathanson6, Jan W Eriksson7. 1. Cardiology Unit, Department of Medicine, Solna, Karolinska Institute, Stockholm, Sweden and Capio S:t Görans Hospital, Stockholm, Sweden. 2. AstraZeneca Europe & Canada, Oslo, Norway. 3. Department of Clinical Science and Education, Division of Internal Medicine, Unit for Diabetes Research, Södersjukhuset, Stockholm, Sweden. 4. Statisticon AB, Uppsala, Sweden. 5. AstraZeneca Nordic-Baltic, Södertälje, Sweden. 6. Division of Internal Medicine, Unit for Diabetes Research, Karolinska University Hospital, Stockholm, Sweden. 7. Department of Medical Sciences, Clinical Diabetes and Metabolism, Uppsala University, Uppsala, Sweden.
Abstract
AIMS: To investigate how the cardiovascular (CV) risk benefits of dapagliflozin translate into healthcare costs compared with other non-sodium-glucose cotransporter-2 inhibitor glucose-lowering drugs (oGLDs) in a real-world population with type 2 diabetes (T2D) that is similar to the population of the DECLARE-TIMI 58 trial. METHODS: Patients initiating dapagliflozin or oGLDs between 2013 and 2016 in Swedish nationwide healthcare registries were included if they fulfilled inclusion and exclusion criteria of the DECLARE-TIMI 58 trial (DECLARE-like population). Propensity scores for the likelihood of dapagliflozin initiation were calculated, followed by 1:3 matching with initiators of oGLDs. Per-patient cumulative costs for hospital healthcare (in- and outpatient) and for drugs were calculated from new initiation until end of follow-up. RESULTS: A total of 24 828 patients initiated a new GLD; 6207 initiated dapagliflozin and 18 621 initiated an oGLD. After matching based on 96 clinical and healthcare cost variables, groups were balanced at baseline. Mean cumulative 30-month healthcare cost per patient was similar in the dapagliflozin and oGLD groups ($11 807 and $11 906, respectively; difference, -$99; 95% CI, -$629, $483; P = 0.644). Initiation of dapagliflozin rather than an oGLD was associated with significantly lower hospital costs (-$658; 95% CI, -$1169, -$108; P = 0.024) and significantly higher drug costs ($559; 95% CI, $471, $648; P < 0.001). Hospital cost difference was related mainly to fewer CV- and T2D-associated complications with use of dapagliflozin compared with use of an oGLD (-$363; 95% CI, -$665, -$61; P = 0.008). CONCLUSION: In a nationwide, real-world, DECLARE-like population, dapagliflozin was associated with lower hospital costs compared with an oGLD, mainly as a result of reduced rates of CV- and T2D-associated complications.
AIMS: To investigate how the cardiovascular (CV) risk benefits of dapagliflozin translate into healthcare costs compared with other non-sodium-glucose cotransporter-2 inhibitor glucose-lowering drugs (oGLDs) in a real-world population with type 2 diabetes (T2D) that is similar to the population of the DECLARE-TIMI 58 trial. METHODS:Patients initiating dapagliflozin or oGLDs between 2013 and 2016 in Swedish nationwide healthcare registries were included if they fulfilled inclusion and exclusion criteria of the DECLARE-TIMI 58 trial (DECLARE-like population). Propensity scores for the likelihood of dapagliflozin initiation were calculated, followed by 1:3 matching with initiators of oGLDs. Per-patient cumulative costs for hospital healthcare (in- and outpatient) and for drugs were calculated from new initiation until end of follow-up. RESULTS: A total of 24 828 patients initiated a new GLD; 6207 initiated dapagliflozin and 18 621 initiated an oGLD. After matching based on 96 clinical and healthcare cost variables, groups were balanced at baseline. Mean cumulative 30-month healthcare cost per patient was similar in the dapagliflozin and oGLD groups ($11 807 and $11 906, respectively; difference, -$99; 95% CI, -$629, $483; P = 0.644). Initiation of dapagliflozin rather than an oGLD was associated with significantly lower hospital costs (-$658; 95% CI, -$1169, -$108; P = 0.024) and significantly higher drug costs ($559; 95% CI, $471, $648; P < 0.001). Hospital cost difference was related mainly to fewer CV- and T2D-associated complications with use of dapagliflozin compared with use of an oGLD (-$363; 95% CI, -$665, -$61; P = 0.008). CONCLUSION: In a nationwide, real-world, DECLARE-like population, dapagliflozin was associated with lower hospital costs compared with an oGLD, mainly as a result of reduced rates of CV- and T2D-associated complications.
Authors: Remo H M Furtado; Marc P Bonaca; Itamar Raz; Thomas A Zelniker; Ofri Mosenzon; Avivit Cahn; Julia Kuder; Sabina A Murphy; Deepak L Bhatt; Lawrence A Leiter; Darren K McGuire; John P H Wilding; Christian T Ruff; Jose C Nicolau; Ingrid A M Gause-Nilsson; Martin Fredriksson; Anna Maria Langkilde; Marc S Sabatine; Stephen D Wiviott Journal: Circulation Date: 2019-03-18 Impact factor: 29.690
Authors: Thomas A Zelniker; Stephen D Wiviott; Itamar Raz; Kyungah Im; Erica L Goodrich; Marc P Bonaca; Ofri Mosenzon; Eri T Kato; Avivit Cahn; Remo H M Furtado; Deepak L Bhatt; Lawrence A Leiter; Darren K McGuire; John P H Wilding; Marc S Sabatine Journal: Lancet Date: 2018-11-10 Impact factor: 79.321
Authors: Stephen D Wiviott; Itamar Raz; Marc P Bonaca; Ofri Mosenzon; Eri T Kato; Avivit Cahn; Michael G Silverman; Thomas A Zelniker; Julia F Kuder; Sabina A Murphy; Deepak L Bhatt; Lawrence A Leiter; Darren K McGuire; John P H Wilding; Christian T Ruff; Ingrid A M Gause-Nilsson; Martin Fredriksson; Peter A Johansson; Anna-Maria Langkilde; Marc S Sabatine Journal: N Engl J Med Date: 2018-11-10 Impact factor: 91.245
Authors: Christian Bommer; Esther Heesemann; Vera Sagalova; Jennifer Manne-Goehler; Rifat Atun; Till Bärnighausen; Sebastian Vollmer Journal: Lancet Diabetes Endocrinol Date: 2017-04-26 Impact factor: 32.069
Authors: Anna Norhammar; Johan Bodegård; Thomas Nyström; Marcus Thuresson; Jan W Eriksson; David Nathanson Journal: Diabetologia Date: 2016-05-18 Impact factor: 10.122
Authors: Jonas F Ludvigsson; Eva Andersson; Anders Ekbom; Maria Feychting; Jeong-Lim Kim; Christina Reuterwall; Mona Heurgren; Petra Otterblad Olausson Journal: BMC Public Health Date: 2011-06-09 Impact factor: 3.295
Authors: Frederik Persson; Thomas Nyström; Marit E Jørgensen; Bendix Carstensen; Hanne L Gulseth; Marcus Thuresson; Peter Fenici; David Nathanson; Jan W Eriksson; Anna Norhammar; Johan Bodegard; Kåre I Birkeland Journal: Diabetes Obes Metab Date: 2017-09-08 Impact factor: 6.577
Authors: David Nathanson; Ugne Sabale; Jan W Eriksson; Thomas Nyström; Anna Norhammar; Urban Olsson; Johan Bodegård Journal: Pharmacoecon Open Date: 2018-12
Authors: Anna Norhammar; Johan Bodegard; Thomas Nyström; Marcus Thuresson; Klas Rikner; David Nathanson; Jan W Eriksson Journal: Diabetes Obes Metab Date: 2019-08-26 Impact factor: 6.577